The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Johnson & Johnson presented significant clinical data at ASCO 2026, featuring promising results for nipocalimab and practice-changing Phase 3 outcomes in prostate cancer and myeloma. The company also announced a $1 billion acquisition of Firefly Bio to access its specialized platform for targeting KRAS-driven tumors. Furthermore, new data showed that the Talvey and Darzalex Faspro combination reduced disease progression risk by 72% in earlier-stage multiple myeloma.